Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Aloukick Kumar Singh, PhD, Elias Schetzen, PhD, Esther BACHAR Lustig, PhD, Wei-Hsin Liu, M.Sc, Raj Kumar Yadav, PhD, Sandeep Kumar Yadav, PhD, Kathryn McGinnis, M.Sc, Yair Reisner, PhD

Blood (2019) 134 (Supplement_1): 1919.

https://doi.org/10.1182/blood-2019-124594

Published: 2019

Journal Articles

Towards Safer Allogeneic HSCT in Autoimmunity: Proof of Concept in Diabetes-Prone Mice

Rakefet Sidlik Muskatel, MD, Bar Nathansohn-Levi, PhD, Esther BACHAR Lustig, PhD, Yair Reisner, PhD

Blood (2019) 134 (Supplement_1): 3212.

https://doi.org/10.1182/blood-2019-124905

Published: 2019

Journal Articles

High Levels of Hematopoietic Progenitors in the Fetal Lung Enable Induction of Immune Tolerance and Co-Transplantation of Epithelial Progenitors for Repair of Lung Injury Across MHC Barriers

Carmit Hillel Karniel, MSc, Chava Rosen, MD PhD, Esther Bachar Lustig, PhD, Elias Shezen, PhD, Yair Reisner, PhD

Blood (2016) 128 (22): 1477.

https://doi.org/10.1182/blood.V128.22.1477.1477

Published: 2016

Journal Articles

Transplantation of T Cell Depleted Haploidentical HSCT Following Non-Myeloablative (NMA) Conditioning: Combining the Power of Megadose Transplants with Post Transplant Cyclophosphamide (PTCY)

Franco Aversa, MD, Esther BacharLustig, PhD, Lucia Prezioso, MD PhD, Sabrina Bonomini, MSc, Noga Or Geva, PhD, Alessandro Monti, MD, Ilenia Manfra, MD, Chiara Schifano, MSc, Federica Galaverna, MD, Yael Zlotnikov Klionsky, PhD, Yair Reisner, PhD

Blood (2016) 128 (22): 5765.

https://doi.org/10.1182/blood.V128.22.5765.5765

Published: 2016

Journal Articles

Towards 'Off-the-Shelf ' Universal Chimeric Antigen Receptor (CAR) T Cells: Mouse Anti-3 rd Party Central Memory CD8 Veto Cells Prolong Functional Engraftment of Allogeneic Genetically Modified T Cells

Noga Or Geva, PhD, Rotem Gidron, MD, Aloukick Kumar Singh, PhD, Rakefet Sidlik Muskatel, MD, Yair Reisner, PhD

Blood (2016) 128 (22): 2171.

https://doi.org/10.1182/blood.V128.22.2171.2171

Published: 2016

Journal Articles

Next Generation Veto Cells for Non-Myeloablative Haploidentical HSCT: Combining Anti-Viral and Graft Facilitating Activity

Esther Bachar Lustig, PhD, Noga Or Geva, PhD, Assaf Lask, PhD, Rotem Gidron, MD, Sivan Kagan, PhD, Aloukick Kumar Sinqh, PhD, Yair Reisner, PhD

Blood (2016) 128 (22): 3345.

https://doi.org/10.1182/blood.V128.22.3345.3345

Published: 2016

Journal Articles

Chimerism Induction Without GVHD Following Low Intensity Conditioning In MHC Disparate Recipients: Combining The Benefit Of Cyclophosphamide Post Transplant With The Tolerogenicity Of Megadose T Cell Depleted HSCT

Esther Bachar-Lustig, PhD, Noga Or-Geva, MSc, Yael Zlotnikov Klionsky, MSc, Yair Reisner, PhD

Blood (2013) 122 (21): 3238.

https://doi.org/10.1182/blood.V122.21.3238.3238

Published: 2013

Journal Articles

Perforin Positive Regulatory DCs In Immune Tolerance: Novel Anti-Inflammatory Players In Metabolic Syndrome

Yael Zlotnikov Klionsky, MSc, Bar Nathansohn, M.Sc, Chava Rosen, MD, Ph.D, Anna Aronovich, Ph.D, Steffen Jung, Ph.D, Elias Shezen, PhD, Oren Yifa, Yair Reisner, PhD

Blood (2013) 122 (21): 784.

https://doi.org/10.1182/blood.V122.21.784.784

Published: 2013

Journal Articles

Towards Clinically Feasible Co-Stimulatory Blockade for Tolerance Induction: Transient Treatment with CTLA4-Ig, Anti-CD48 and FTY720 Enables Durable Engraftment of T Cell Depleted BM Allografts Following Non-Myeloablative Conditioning.

Esther Bachar-Lustig, PhD, Dalit Tchorsh-Yutsis, PhD, Eran Ophir, MSc, Yael Zlotnikov Klionsky, MSc, Noga Or-Geva, BSc, Yair Reisner, PhD

Blood (2010) 116 (21): 3726.

https://doi.org/10.1182/blood.V116.21.3726.3726

Published: 2010

Journal Articles

Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model

Assaf Lask, MSc, Eran Ophir, MSc, Noga Or-Geva, BSc, Adva Cohen, MSc, Ran Afik, MSc, Yaki Eidelstein, MSc, Robert Negrin, MD, Arnon Nagler, M.D., Alain Berrebi, MD, David Hagin, MD, Yair Reisner, PhD

Blood (2010) 116 (21): 424.

https://doi.org/10.1182/blood.V116.21.424.424

Published: 2010

Journal Articles

A Novel Mechanism for CTL Mediated Veto Activity: CTLs Respond to Recognition by Alloreactive T Cell with Activation and Cytotoxic Granule Secretion.

Oren Milstein, MSc, Assaf Lask, MSc, Shlomit Reich-Zeliger, PhD, Yair Reisner, PhD

Blood (2007) 110 (11): 2303.

https://doi.org/10.1182/blood.V110.11.2303.2303

Published: 2007

Journal Articles

Eradication of B Cell Malignancies by Anti-3 rd Party CTLs: A Novel Role for MHC Class I.

Assaf Lask, MSc, Polina Goichberg, PhD, Rinat Goren-Arbel, PhD, Oren Milstein, MSc, Shraga Aviner, MD, Ilan Feine, Tirza Klein, PhD, Alain Berrebi, MD, Yair Reisner, PhD

Blood (2007) 110 (11): 2759.

https://doi.org/10.1182/blood.V110.11.2759.2759

Published: 2007

Journal Articles

The Role of ERK and XIAP in Tolerance Induction by Veto CTLs.

Shlomit Reich-zeliger, PhD, Yaki Edelshtein, MsC, David Hagin, MD, Rony Seger, PhD, Yair Reisner, PhD

Blood (2007) 110 (11): 3256.

https://doi.org/10.1182/blood.V110.11.3256.3256

Published: 2007

Journal Articles

The Role of ERK5 Signaling in Tolerance Induction by Veto CTLs.

Shlomit Reich-Zeliger, PhD, Tamar Hanoch, MSc, Rony Seger, PhD, Yair Reisner, PhD

Blood (2005) 106 (11): 3302.

https://doi.org/10.1182/blood.V106.11.3302.3302

Published: 2005

Journal Articles

Overcoming Rejection of Bone Marrow Allografts by Treg Cells in a Stringent Mouse Model for T Cell Mediated Rejection: Tolerance Induction by Third Party “Off-the-Shelf” Cells.

David Steiner, PhD, Noga Brunicki, MSc, Esther Bachar-Lustig, PhD, Yair Reisner, PhD

Blood (2005) 106 (11): 576.

https://doi.org/10.1182/blood.V106.11.576.576

Published: 2005

Journal Articles

Eradication of B-Lymphoma by Allogeneic Anti-Third Party Host Non-Reactive CTLs: Growing Evidence for TCR Independent Reactivity Against B-Cell Malignancies.

Shraga Aviner, MD, Fabian D. Arditti, PhD, Rinat Arbel-Goren, PhD, Tirza Klein, PhD, Yair Reisner, PhD

Blood (2004) 104 (11): 3055.

https://doi.org/10.1182/blood.V104.11.3055.3055

Published: 2004

Journal Articles

Effective Deletion of Anti-Donor Host Memory Effector Cells by Anti-3rd Party Veto CTLs: Implications to Tolerance Induction in Presensitized Bone Marrow Recipients.

Shlomit Reich-Zeliger, PhD, Esther Bachar-Lustig, PhD, Yair Reisner, PhD

Blood (2004) 104 (11): 44.

https://doi.org/10.1182/blood.V104.11.44.44

Published: 2004

NARROW

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Towards Safer Allogeneic HSCT in Autoimmunity: Proof of Concept in Diabetes-Prone Mice

High Levels of Hematopoietic Progenitors in the Fetal Lung Enable Induction of Immune Tolerance and Co-Transplantation of Epithelial Progenitors for Repair of Lung Injury Across MHC Barriers

Transplantation of T Cell Depleted Haploidentical HSCT Following Non-Myeloablative (NMA) Conditioning: Combining the Power of Megadose Transplants with Post Transplant Cyclophosphamide (PTCY)

Towards 'Off-the-Shelf ' Universal Chimeric Antigen Receptor (CAR) T Cells: Mouse Anti-3 rd Party Central Memory CD8 Veto Cells Prolong Functional Engraftment of Allogeneic Genetically Modified T Cells

Next Generation Veto Cells for Non-Myeloablative Haploidentical HSCT: Combining Anti-Viral and Graft Facilitating Activity

Chimerism Induction Without GVHD Following Low Intensity Conditioning In MHC Disparate Recipients: Combining The Benefit Of Cyclophosphamide Post Transplant With The Tolerogenicity Of Megadose T Cell Depleted HSCT

Perforin Positive Regulatory DCs In Immune Tolerance: Novel Anti-Inflammatory Players In Metabolic Syndrome

Towards Clinically Feasible Co-Stimulatory Blockade for Tolerance Induction: Transient Treatment with CTLA4-Ig, Anti-CD48 and FTY720 Enables Durable Engraftment of T Cell Depleted BM Allografts Following Non-Myeloablative Conditioning.

Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model

A Novel Mechanism for CTL Mediated Veto Activity: CTLs Respond to Recognition by Alloreactive T Cell with Activation and Cytotoxic Granule Secretion.

Eradication of B Cell Malignancies by Anti-3 rd Party CTLs: A Novel Role for MHC Class I.

The Role of ERK and XIAP in Tolerance Induction by Veto CTLs.

The Role of ERK5 Signaling in Tolerance Induction by Veto CTLs.

Overcoming Rejection of Bone Marrow Allografts by Treg Cells in a Stringent Mouse Model for T Cell Mediated Rejection: Tolerance Induction by Third Party “Off-the-Shelf” Cells.

Eradication of B-Lymphoma by Allogeneic Anti-Third Party Host Non-Reactive CTLs: Growing Evidence for TCR Independent Reactivity Against B-Cell Malignancies.

Effective Deletion of Anti-Donor Host Memory Effector Cells by Anti-3rd Party Veto CTLs: Implications to Tolerance Induction in Presensitized Bone Marrow Recipients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only